U.S. Markets closed

Oragenics, Inc. (OGEN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.6616+0.0165 (+2.56%)
At close: 4:00PM EDT

Oragenics, Inc.

4902 Eisenhower Boulevard
Suite 125
Tampa, FL 33634
United States
813 286 7900

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. Alan F. JoslynPres, CEO & Director526.64kN/A1959
Mr. Michael O. Sullivan CPACFO, Sec. & Treasurer297.21kN/A1956
Dr. Martin HandfieldSr. VP of Discovery Research250.05kN/A1971
Dr. Raman BediChairman of International Scientific Advisory Board and Sr. ConsultantN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Corporate Governance

Oragenics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.